Wednesday, July 8, 2026

Patent intelligence · US

US 12275788

Single-domain antibodies against CD33 and constructs thereof

granted A61KA61K2039/505A61K2239/29A61K2239/31
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 26
Patent details — US 12275788
Jurisdiction
US
Status
granted
Grant date
Apr 15, 2025
Expiration
Apr 10, 2045
Claims
18
CPC classes
A61K, A61K2039/505, A61K2239/29, A61K2239/31
View on Google Patents ↗

Quick answer

US 12275788 (Single-domain antibodies against CD33 and constructs thereof) is held by Legend Biotech Ireland Limited. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K2039/505, A61K2239/29, A61K2239/31, A61K2239/38, A61K2239/48

More from Legend Biotech Ireland Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Legend Biotech Ireland Limited · Expires Sep 18, 2045

    granted
  2. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    LEGEND BIOTECH USA INC. · Expires Jul 3, 2045

    granted
  3. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Nanjing Legend Biotech Co., Ltd · Expires Mar 20, 2045

    granted
  4. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Expires Feb 27, 2045

    granted
  5. US 12168688

    Antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Expires Dec 12, 2044

    granted
  6. US 12097219

    Single-domain antibodies against CLL1 and constructs thereof

    Legend Biotech Ireland Limited · Expires Sep 19, 2044

    granted
  7. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    BioLegend, Inc. · Expires Jun 6, 2044

    granted

Frequently asked questions

What is US patent 12275788?

US 12275788 (Single-domain antibodies against CD33 and constructs thereof) is held by Legend Biotech Ireland Limited. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12275788?

Legend Biotech Ireland Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 12275788 expire?

Our index shows an expiration date of Apr 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.